Related Experiment Video

Updated: Jun 3, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Discovery of triazine-benzimidazoles as selective inhibitors of mTOR

Emily A Peterson1, Paul S Andrews, Xuhai Be

  • 1Medicinal Chemistry, Amgen Inc, 360 Binney St, Cambridge, MA 02142, USA. epeterso@amgen.com

Bioorganic & Medicinal Chemistry Letters
|March 8, 2011
PubMed

Insights

Researchers discovered novel triazine benzimidazole compounds that selectively inhibit mTOR kinase, a key target in cancer therapy. These inhibitors show promise in reducing cancer cell proliferation and tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Medicinal Chemistry

Background:

  • The mammalian target of rapamycin (mTOR) pathway is crucial for cell growth and survival.
  • Dysregulation of the mTOR pathway is implicated in various cancers, making it a significant therapeutic target.

Purpose of the Study:

  • To discover and characterize novel inhibitors targeting mTOR kinase activity.
  • To develop selective inhibitors with improved efficacy and reduced off-target effects compared to PI3Kα.

Main Methods:

  • Synthesis and screening of triazine benzimidazole derivatives.
  • Biochemical assays to determine kinase inhibitory activity and selectivity.
  • In vitro evaluation of antiproliferative effects in cancer cell lines.
  • In vivo pharmacodynamic studies in murine models.

Main Results:

  • Discovery of potent triazine benzimidazole inhibitors of mTOR kinase.
  • Achieved up to 200-fold selectivity for mTOR over PI3Kα.
  • Demonstrated significant inhibition of cancer cell proliferation (mean IC(50) of 0.41 μM).
  • Lead compound 42 showed substantial inhibition of mTOR substrate phosphorylation in vivo.

Conclusions:

  • Triazine benzimidazole compounds represent a promising class of selective mTOR inhibitors.
  • These inhibitors exhibit potent anticancer activity in vitro and in vivo.
  • Further development of these compounds could lead to novel oncology therapeutics.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...